title: Species difference in the mechanism of nonlinear pharmacokinetics of E2074, a novel sodium channel inhibitor, in rats, dogs, and monkeys.
abstract: New chemical entities often exhibit nonlinear pharmacokinetics (PK) profiles in experimental animals. However, the number of studies that have focused on species differences in nonlinear PK is very limited; thus, the aim of this study was to clarify the mechanism of the nonlinear PK of E2074 (2-[(2R)-2-fluoro-3-{(3r)-[(3-fluorobenzyl)oxy]-8-azabicyclo[3.2.1]oct-8-yl}propyl]-4,5-dimethyl-2,4-dihydro-3H-1,2,4-triazol-3-one), a novel sodium channel inhibitor, in rats, dogs, and monkeys. Nonlinear PK profiles with more than dose-proportional increases of Cmax and area under the plasma concentration curve were observed in all species after oral administration. The Michaelis-Menten constant (Km) values of hepatic microsomal metabolism were 7.23 and 0.41 μM in rats and dogs in vitro, respectively, which were lower than the unbound maximum plasma concentrations after oral administration in vivo, indicating that the nonlinear PK in rats and dogs was attributable to the saturation of hepatic metabolism. However, we do not believe that the saturation of hepatic metabolism was the mechanism of nonlinearity in monkeys because of the high Km value (42.44 μM) observed in liver microsomes. Intestinal metabolism was observed in monkey intestinal microsomes but not in rats and dogs, and the nonlinear PK in monkeys was diminished by inhibition of intestinal metabolism with a concomitant oral dose of ketoconazole. These results suggest that saturation of the intestinal metabolism is the potential mechanism of nonlinearity in monkeys. P-glycoprotein was not involved in the nonlinear PK profiles in any species. In conclusion, the mechanism of the nonlinear PK of E2074 is species dependent, with the saturation of hepatic metabolism in rats and dogs and that of intestinal metabolism in monkeys being the primary cause.
authors: Drug Metabolism and Pharmacokinetics Japan, Eisai Product Creation Systems, Eisai Co., Ltd., 1-3, Tokodai 5-Chome Tsukuba-shi, Ibaraki 300-2635, Japan. y-nagaya@hhc.eisai.co.jp
authors: Yoko
authors: Y
authors: Nagaya
authors: Osamu
authors: O
authors: Takenaka
authors: Kazutomi
authors: K
authors: Kusano
authors: Tsutomu
authors: T
authors: Yoshimura
mesh_terms: D000818:Animals; D004285:Dogs; D007413:Intestinal Mucosa / Q000378:metabolism; D008252:Macaca fascicularis; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D026941:Sodium Channel Blockers / Q000493:pharmacokinetics*; D013045:Species Specificity; D014230:Triazoles / Q000493:pharmacokinetics*; D014326:Tropanes / Q000493:pharmacokinetics*
chemical_list: C584003:2-(2-fluoro-3-(((3-fluorobenzyl)oxy)-8-azabicyclo(3.2.1)oct-8-yl)propyl)-4,5-dimethyl-2,4-dihydro-3H-1,2,4-triazol-3-one; D026941:Sodium Channel Blockers; D014230:Triazoles; D014326:Tropanes